Free Trial

Rein Therapeutics (RNTX) Stock Forecast & Price Target

Rein Therapeutics logo
$1.19 +0.07 (+6.25%)
As of 09/24/2025 04:00 PM Eastern

Rein Therapeutics - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Sell
0
Hold
1
Buy
1

Based on 2 Wall Street analysts who have issued ratings for Rein Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 2 analysts, 1 has given a hold rating, and 1 has given a buy rating for RNTX.

Consensus Price Target

$10.00
740.34% Upside
According to the 2 analysts' twelve-month price targets for Rein Therapeutics, the average price target is $10.00. The highest price target for RNTX is $10.00, while the lowest price target for RNTX is $10.00. The average price target represents a forecasted upside of 740.34% from the current price of $1.19.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for RNTX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Rein Therapeutics and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

RNTX Analyst Ratings Over Time

TypeCurrent Forecast
9/25/24 to 9/25/25
1 Month Ago
8/26/24 to 8/26/25
3 Months Ago
6/27/24 to 6/27/25
1 Year Ago
9/26/23 to 9/25/24
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
N/A N/A
Buy
1 Buy rating(s)
0 Buy rating(s)
N/A N/A
Hold
1 Hold rating(s)
1 Hold rating(s)
N/A N/A
Sell
0 Sell rating(s)
0 Sell rating(s)
N/A N/A
Consensus Price Target$10.00N/AN/AN/A
Forecasted Upside740.34% UpsideN/AN/AN/A
Consensus RatingModerate BuyHoldN/AN/A

RNTX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

RNTX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Rein Therapeutics Stock vs. The Competition

TypeRein TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.50
2.78
2.53
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside740.34% Upside1,730.48% Upside11.57% Upside
News Sentiment Rating
Positive News

See Recent RNTX News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
9/22/2025HC Wainwright
1 of 5 stars
Brandon Folkes
Brandon Folkes
Not Rated
Initiated CoverageBuy$10.00+726.44%
8/19/2025Brookline Capital Management
5 of 5 stars
Kemp Dolliver
Kemp Dolliver
Not Rated
DowngradeBuyHold

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 07:38 AM ET.


RNTX Forecast - Frequently Asked Questions

According to the research reports of 2 Wall Street equities research analysts, the average twelve-month stock price forecast for Rein Therapeutics is $10.00, with a high forecast of $10.00 and a low forecast of $10.00.

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Rein Therapeutics in the last twelve months. There is currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" RNTX shares.

According to analysts, Rein Therapeutics's stock has a predicted upside of 740.34% based on their 12-month stock forecasts.

Over the previous 90 days, Rein Therapeutics's stock had 1 downgrade by analysts.

Rein Therapeutics has been rated by research analysts at Brookline Capital Management, and HC Wainwright in the past 90 days.

Analysts like Rein Therapeutics less than other "medical" companies. The consensus rating score for Rein Therapeutics is 2.50 while the average consensus rating score for "medical" companies is 2.78. Learn more on how RNTX compares to other companies.


This page (NASDAQ:RNTX) was last updated on 9/25/2025 by MarketBeat.com Staff
From Our Partners